Association between the 5-HTTLPR polymorphism and response to citalopram in Turkish patients with major depressive disorder

Basit Öğe Kaydı
dc.contributor.authorUckun Z.
dc.contributor.authorBaskak B.
dc.contributor.authorOzdemir H.
dc.contributor.authorOzelkizil E.T.
dc.contributor.authorDevrimci Ozguven H.
dc.contributor.authorSuzen H.S.
dc.date.accessioned2020-06-25T15:17:43Z
dc.date.available2020-06-25T15:17:43Z
dc.date.issued2016
dc.departmentKırıkkale Üniversitesi
dc.description.abstractThe objective of this study was to investigate the relationship between the genetic polymorphism of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the response to citalopram treatment and side effects in Turkish patients with major depressive disorder. The study involved 51 patients who received 10-40 mg/day of citalopram for 4 to 6 weeks. Clinical symptoms were evaluated by the 17-item Hamilton Depression Rating (HAMD-17) scale, Clinical Global Impression (CGI) and UKU side effect rating scale (UKU) at weeks 4 and/or 6. The 5-HTTLPRL/S polymorphism was determined by slowdown-polymerase chain reaction method. Of the fifty-one patients, 13 (26%) were the LL genotype, 21 (41%) were the LS genotype, 17 (33%) were the SS genotype. L allele seems to be associated with better response due to odds ratio for L allele versus S allele despite statistically insignificant. In terms of CGI-Severity scale, The LL genotype versus the LS genotype had a higher risk at the week 6 (P<0.05). On the other hand, apart from this comparison, there is no significant difference in CGI-Severity and Improvement and UKU scales according to the distribution of genotypes at week 4 and/or 6. However, these findings surely need further investigation and confirmation. © 2016, Turkish Pharmacists Association. All rights reserved.en_US
dc.identifier.endpage158en_US
dc.identifier.issn1304530X
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84980022863
dc.identifier.scopusqualityQ2
dc.identifier.startpage145en_US
dc.identifier.trdizinid203609
dc.identifier.urihttps://hdl.handle.net/20.500.12587/2497
dc.identifier.volume13en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherTurkish Pharmacists Associationen_US
dc.relation.ispartofTurkish Journal of Pharmaceutical Sciences
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject5-HTTLPR polymorphismen_US
dc.subjectCitalopramen_US
dc.subjectSide effectsen_US
dc.subjectTreatment responseen_US
dc.titleAssociation between the 5-HTTLPR polymorphism and response to citalopram in Turkish patients with major depressive disorderen_US
dc.title.alternativeMajor Depresif Bozukluğu Olan Türk Hastalarda 5-HTTLPR Polimorfizmin ve Sitalopram Yanıtı Arasındaki İlişkisien_US
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu